Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia

Francesco Buccisano, Luca Maurillo, Maria Ilaria Del Principe, Giovanni Del Poeta, Giuseppe Sconocchia, Francesco Lo-Coco, William Arcese, Sergio Amadori, Adriano Venditti

Research output: Contribution to journalArticlepeer-review


The choice of either induction or postremission therapy for adults with acute myeloid leukemia is still largely based on the "one size fits all" principle. Moreover, pretreatment prognostic parameters, especially chromosome and gene abnormalities, may fail in predicting individual patient outcome. Measurement of minimal residual disease (MRD) is nowadays recognized as a potential critical tool to assess the quality of response after chemotherapy and to plan postremission strategies that are, therefore, driven by the individual risk of relapse. PCR and multiparametric flow cytometry have become the most popular methods to investigate MRD because they have been established as sensitive and specific enough to allow MRD to be studied serially. In the present review, we examine the evidence supporting the appropriateness of incorporating MRD detection into the AML risk assessment process. A comprehensive prognostic algorithm, generated by combining pretreatment cytogenetics/genetics and posttreatment MRD determination, should promote advances in development of personalized therapeutic approaches.

Original languageEnglish
Pages (from-to)332-341
Number of pages10
Issue number2
Publication statusPublished - Jan 12 2012

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology


Dive into the research topics of 'Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this